Epinephrine-Containing Lidocaine and Hematoma Risk After Image-Guided Core-Needle Breast Biopsy
Journal of Breast Imaging · 2025
DOI: 10.1093/jbi/wbaf026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Breast Imaging, 2025. Verfasst von Eric E Davis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Epinephrine, Lidocaine, Hematoma, Image-Guided Biopsy. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate the risk of symptomatic hematomas in patients receiving epinephrine-containing lidocaine compared with lidocaine alone after core-needle breast biopsies (CNBBs). The efficacy of epinephrine-containing lidocaine in reducing hematoma risk following image-guided CNBB remains unclear.
Methods
A single-institution, retrospective review of all CNBBs performed during a 6-month period using lidocaine alone (September 1, 2022, to March 15, 2023) due to a national shortage of epinephrine-containing lidocaine and a 6-month period using epinephrine-containing lidocaine (April 1, 2023, to October 1, 2023). A nurse navigator contacted all patients postbiopsy to assess postprocedural complications, including symptomatic hematomas. Postprocedure mammograms were reviewed for detectable hematomas after 9-gauge and 12- to 14-gauge CNBBs. Logistic regression models evaluated the associations between epinephrine-containing lidocaine use and symptomatic and mammographically evident hematomas.
Results
A total of 1157 CNBBs were performed in 967 patients; 619 received epinephrine-containing lidocaine and 538 received lidocaine alone. There were 11 (1.0%; 11/1157) symptomatic hematomas, 10 of which occurred following 9-gauge CNBBs (6 with stereotactic/tomosynthesis guidance and 4 with MRI guidance). There was no significant difference in the occurrence of symptomatic hematomas (P = .34) or mammographically evident hematomas (P = .53) after 12- to 14-gauge US-guided CNBBs performed with epinephrine-containing lidocaine vs lidocaine alone. Fewer symptomatic hematomas occurred after 9-gauge CNBBs in the epinephrine-containing lidocaine group (0.6%; 2/310) compared with the lidocaine alone (4.1%; 8/194) (P = .02). After 9-gauge CNBBs, mammographically evident hematomas were less frequent (16.1% vs 41.2%; P <.0001) with epinephrine-containing lidocaine compared with lidocaine alone.
Conclusion
Epinephrine-containing lidocaine reduced rates of symptomatic and mammographically detected hematomas after 9-gauge CNBBs. Local infiltration with epinephrine-containing lidocaine could be considered in 9-gauge CNBBs to reduce hematoma risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
- Department of Radiology, University of North Carolina, Chapel Hill, NC, USA.
ORCID-Profile: Genevieve A Woodard, Bonnie N Joe, Amie Y Lee
Zitieren
APA
Davis, E. E., Mark, S., Woodard, G. A., Tang, F., Gellatly, M., Hayward, J. H., Ray, K. M., Joe, B. N., Lee, A. Y., & Chung, M. (2025). Epinephrine-Containing Lidocaine and Hematoma Risk After Image-Guided Core-Needle Breast Biopsy. Journal of Breast Imaging. https://doi.org/10.1093/jbi/wbaf026
Vancouver
Davis EE, Mark S, Woodard GA, Tang F, Gellatly M, Hayward JH, et al. Epinephrine-Containing Lidocaine and Hematoma Risk After Image-Guided Core-Needle Breast Biopsy. Journal of Breast Imaging. 2025. doi:10.1093/jbi/wbaf026
BibTeX
@article{Davis2025,
author = {Davis, Eric E and Mark, Sueann and Woodard, Genevieve A and Tang, Felicia and Gellatly, Matthew and Hayward, Jessica H and Ray, Kimberly M and Joe, Bonnie N and Lee, Amie Y and Chung, Maggie},
title = {Epinephrine-Containing Lidocaine and Hematoma Risk After Image-Guided Core-Needle Breast Biopsy},
journal = {Journal of Breast Imaging},
year = {2025},
doi = {10.1093/jbi/wbaf026}
}
EUVIMED